40 results about "Immuno therapy" patented technology

The invention relates to the field of biological medicines, in particular to a tumor antigen peptide and application thereof. The tumor antigen peptide provided by the invention comprises a peptide fragment with an amino acid sequence as shown in SEQ ID No.1. The tumor antigen peptide provided by the invention can be presented by the highest frequency HLA subtype (HLA-A * 11: 01) of Chinese population. In addition, through an in-vitro stimulation mode, it is verified that the tumor antigen peptide can effectively stimulate specific T cells, and a specific TCR element is successfully obtained. Therefore, a direct foundation is laid for further developing a TCR-T therapy, a therapeutic vaccine and other immunotherapies of the targeted human TP53R248Q.

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The present invention relates to: a temperature-sensitive hydrogel for cancer treatment; a photothermal composition comprising the hydrogel as an active ingredient; and a preparation method for the temperature-sensitive hydrogel for cancer treatment. The temperature-sensitive hydrogel of the present invention includes gold nanostars as active ingredients, and thus can generate heat by light irradiation, thereby exhibiting a photothermal therapy effect. In addition, the hydrogel temperature increases so that the release of nitric oxide (NO) from S-nitrosocysteine can be induced. In addition, the temperature-sensitive hydrogel of the present invention includes S-nitrosocysteine as an active ingredient so that, upon a temperature rise due to a photothermal reaction, the penetration of drugs into a tumor site can be improved by the release of NO, and at the same time, apoptosis of cancer cells can be directly caused; and includes an immunotherapy agent as an active ingredient so that tumor size can be effectively suppressed even with the passage of time. Therefore, as a material that enables complex treatment combined with photothermal therapy and immunotherapy, the temperature-sensitive hydrogel of the present invention having the aforementioned effect can be usefully utilized in the field of medicine for cancer treatment.

Disclosed herein are methods of using OX40 as a biomarker for predicting clinical sensitivity and therapeutic response of subjects having cancer to treatment with immunotherapeutic agents, and methods of using OX40 as a biomarker for selecting patient population for cancer treatment with immunotherapeutic agents. Disclosed herein are also methods of treating OX40-expressing cancers using immunotherapeutic agents. Further provided herein are kit for predicting the responsiveness of a subject having cancer to treatment with immunotherapeutic agents.

The invention relates to the field of biological medicines, in particular to application of an IL-6 inhibitor in preparation of a myocarditis treatment medicine or a tumor treatment medicine enhancer. The IL-6 inhibitor is used as a medicine for treating myocarditis and is immune checkpoint inhibitor related myocarditis. The IL-6 inhibitor is targeted to an IL-6 / JAK2 / STAT3 signal channel, the potential of relieving myocarditis induced by the immune checkpoint inhibitor is achieved, and the anti-tumor immune response of the immune checkpoint inhibitor is enhanced when the IL-6 inhibitor and the immune checkpoint inhibitor are jointly applied. The invention also provides the first combined application of the IL-6 inhibitor and the immune checkpoint inhibitor in the animal model, and opens up a new way for the combined application of immunotherapy.

The present invention relates to a method for selecting a patient group predicted to respond to immunotherapy cancer treatment. According to the method of the present invention, it is possible to distinguish, in advance, between a patient group that is likely to respond to anti-TIGIT and / or anti-IL-6 immunotherapeutic agents and a patient group that is unlikely to respond to same, enabling effective treatment to be performed, and thus the method is expected to be widely applicable in the medical field.

Aspects of the present disclosure are directed to methods and compositions for diagnosing and / or treating a subject having cancer. Certain aspects relate to treatment with a cancer therapy and a YTHDF2 inhibitor or a pharmaceutical composition comprising a cancer therapy and a YTHDF2 inhibitor. In some aspects, the YTHDF2 inhibitor includes an oligonucleotide targeting YTHDF2 mRNA or a small molecule inhibitor of YTHDF2. In some aspects, a subject has been determined to have or to have had resistance to a previous cancer treatment, such as radiotherapy and / or immunotherapy.

Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.

The present invention relates to combinations of host cells expression antigen binding proteins that specifically bind to a tumor expressed Preferentially Expressed Antigen of Melanoma (PRAME) antigenic peptide in a complex with MHC, and mRNAs encoding PRAME antigenic peptides. The invention further relates to combined TCR-T / mRNA therapy employing said mRNAs and host cells. In particular, a combined TCR-T / mRNA therapy is provided for use in cancer treatment.

To provide an illumination system, in particular for medical technical therapeutic and / or diagnostic systems.SOLUTION: An illumination system (1) includes at least one laser light source (10) and a light guide (30) which, at a proximal end, is connectable and / or assignable to the at least one laser light source. The illumination system has, at a distal end of the light guide, a diffuser element (40) which has a substantially radial, spherical emission characteristic. The diffuser element comprises at least one diffuser main body. The diffuser main body comprises an inorganic material, in particular a glass, a glass ceramic, a glass-like material, or a composite material of these materials, and advantageously at least one scattering element. A surface of the at least one diffuser main body is pore-free and smooth. Such an illumination system can be used in photodynamic therapy (PDT), photoimmunotherapy (PIT), and ophthalmic and dental fields.SELECTED DRAWING: Figure 1

This invention provides compositions for drug delivery in cancer treatment and immunotherapy. [Solution] A composition is provided comprising polymer gelatin, silicate nanoparticles, and a therapeutic agent having a molecular weight of less than 1000 daltons, wherein the gelatin, the silicate nanoparticles, and the therapeutic agent form a shear-thinning hydrogel.

Provided are a combined therapy of photodynamic therapy and immunological therapy, comprising the combined administration of a porphyrin dimer salt-based photosensitizer and an immune checkpoint inhibitor, and the use thereof in treatment of recurrent and / or metastatic cancers, in particular esophageal cancer.

Disclosed herein is the use of a copper chelating agent or an agent capable of inducing a copper chelating agent for the treatment of cancer, in particular for increasing the efficiency of an immunotherapy for the treatment of cancer. Disclosed herein are methods of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a copper chelating agent or a copper chelating agent inducer in combination with a therapeutically effective amount of an anti-cancer immunotherapeutic agent. Also disclosed herein are kits or combinations and compositions comprising a copper chelating agent or a copper chelating agent inducer and an anti-cancer immunotherapeutic agent, and uses thereof for the treatment of cancer.

The immunotherapy compound comprises an NK cell binding domain, an NK activation domain, and a targeting domain. The targeting domain selectively binds to HER2, HER3, or HER2 / HER3 heterodimer complexes and operably links to the NK activation domain and the NK cell binding domain. The compound may be administered to a subject for the induction of NK-mediated apoptosis of cancer cells, stimulation of NK cell expansion in the subject, and / or cancer treatment.

The present invention relates to single therapy comprising an effective amount of a MDM2 inhibitor, as well as combination therapies comprising an effective amount of a modulator of the immune checkpoint molecule; and an effective amount of a MDM2 inhibitor, wherein the MDM2 inhibitor is represented by the following formula or a pharmaceutically acceptable salt thereof.

A SNP-based model for predicting the occurrence of irAEs induced by immunotherapy. The dbSNP database rs541169 and a single nucleotide polymorphism (SNP) site in the TMEM162 (FAM187B) gene are closely correlated with the occurrence of irAEs. The rs541169 can be advantageously used as a biomarker for predicting the occurrence of irAEs induced by immunotherapy or predicting responsiveness to immunotherapy.

The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and / or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and / or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.

The present disclosure relates to methods of treating cancer in a subject by administering to the subject effective amounts of an anti-CCR8 antibody, a chemotherapeutic agent (e.g., cisplatin, gemcitabine, docetaxel), and a PD1 inhibitor or a PD-L1 inhibitor. In some embodiments, the chemotherapeutic agent is administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody. In some embodiments, the chemotherapeutic agents are co-administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody.

The invention relates to T cells, and to methods of producing tissue-resident memory T cells (TRM). The invention concerns tissue-resident memory T cells (TRM) per se which have been obtained from the methods of the invention, compositions comprising these TRM cells, and the use of these TRM cells and the compositions in therapy, such as in immuno-therapy for treating cancer.

The present invention generally relates to therapeutic compositions and methods for treating cancer patients. The compositions and methods can increase efficacy of an anti-cancer therapy, or treat, prevent, or inhibit an oncology-treatment induced condition (OTIC) induced by an anti-cancer therapy. The therapeutic compositions comprise microbial compositions and, optionally, an anti-cancer therapeutic agent. The methods comprise administering a therapeutic composition comprising a microbial composition and administering an anti-cancer therapy.

The present invention relates to a method for diagnosing whether anticancer therapy will exhibit responsiveness in a particular patient. The anticancer therapy may include chemotherapy or cancer immunotherapy. Specifically, whether anticancer therapy will exhibit responsiveness in a particular patient can be confirmed through a TCTP level in the plasma of the corresponding patient. In such an aspect, the present invention also relates to use of plasma TCTP as a biomarker indicative of responsiveness to anticancer therapy.

This invention relates to biomarkers for predicting the therapeutic responsiveness of cancer patients to immune checkpoint inhibitors. Since gene signatures and gene markers based on a specific pattern demonstrate significantly superior predictive power regarding the therapeutic responsiveness of cancer patients to immuno-anticancer drugs, it is possible to select patient groups predicted to show a therapeutic effect and perform appropriate treatment, thereby reducing patient suffering and costs.

The present invention relates to a method for selecting a patient group predicted to respond to immunotherapy cancer treatment. According to the method of the present invention, it is possible to distinguish, in advance, between a patient group that is likely to respond to anti-TIGIT and / or anti-IL-6 immunotherapeutic agents and a patient group that is unlikely to respond to same, enabling effective treatment to be performed, and thus the method is expected to be widely applicable in the medical field.

The present application provides methods of treating a disease, such as Pompe disease, in a subject, comprising detecting an erythropoiesis biomarker in a sample of the subject after administration of methotrexate and a therapeutic agent to the subject, and administering further treatment with or without concurrently administering additional immune tolerance induction or immunosuppression therapy based on the level of the erythropoiesis biomarker. Further provided by the present application are methods and kits for assessing the level of immune tolerance to a therapeutic agent in a subject based on detection of an erythropoiesis biomarker after administration of methotrexate and the therapeutic agent to the subject.

The present invention relates to an inverse opal (IOPAL) hydrogel formed with poly(ethylene)glycol (PEG) covalently bonded to heparin (Hep) and having a storage shear modulus (G') between 2.5 and 4 kPa. Said hydrogel with improved mechanical and structural properties has demonstrated to be highly effective in CAR T cell expression and, therefore, in CAR T adoptive cell therapy.

An image depicting a tissue sample is received. One or more tissue compartments present in the image of the tissue sample are identified including by generating a compartment map identifying pixels in the image depicting the tissue compartments. One or more cells present in the image of the tissue sample are identified including by generating a cell map identifying pixels in the image depicting the cells. A density-based pathology signature for the image of the tissue sample is determined based on the compartment map and the cell map. The density-based pathology signature includes a density of each cell type present in the one or more tissue compartments. A response computation model is applied to determine, based on the density-based pathology signature, a predictive output indicative of a likelihood of a patient associated with the tissue sample responding to an anticancer therapy such as immunotherapy.

The invention relates to an in vitro method for predicting the early progression of cancer in a subject undergoing immunotherapy. This method comprises determining, in a blood sample isolated from the subject, the total concentration of circulating cell-free DNA and the concentration of large circulating cell-free DNA fragments, combining these data in a mathematical function to obtain a score, and comparing this score to a predetermined reference value. It concludes that the subject exhibits early progression during immunotherapy treatment when the score obtained is less than or equal to the reference value.

The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).

This invention relates to an oral immunotherapy (OIT) composition comprising granules that contain an allergenic protein, such as peanut protein, along with a humectant, such as trehalose, and a binder, such as hypromellose. The composition may further comprise a filler, such as mannitol and a lubricant, such as stearic acid. OIT compositions, methods of preparing OIT compositions and methods of treatment of food allergy using OIT compositions are provided.

The invention relates to an in vitro method for predicting the early progressor character of a subject suffering from cancer during an immunotherapy treatment. This method comprises determining, in a blood sample isolated from the subject, the total concentration of circulating free DNA and a concentration of large circulating free DNA fragments, combining these data in a mathematical function so as to obtain a score, and comparing this score to a predetermined reference value. It concludes that the subject has an early progressor character during the immunotherapy treatment when the score obtained is less than or equal to the reference value.